74 related articles for article (PubMed ID: 24643363)
1. Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells.
Ku BM; Lee CH; Lee SH; Kim SY
Amino Acids; 2014 Jun; 46(6):1527-36. PubMed ID: 24643363
[TBL] [Abstract][Full Text] [Related]
2. Allosteric inhibition site of transglutaminase 2 is unveiled in the N terminus.
Kim N; Kang JH; Lee WK; Kim SG; Lee JS; Lee SH; Park JB; Kim KH; Gong YD; Hwang KY; Kim SY
Amino Acids; 2018 Nov; 50(11):1583-1594. PubMed ID: 30105541
[TBL] [Abstract][Full Text] [Related]
3. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma.
Ku BM; Kim DS; Kim KH; Yoo BC; Kim SH; Gong YD; Kim SY
FASEB J; 2013 Sep; 27(9):3487-95. PubMed ID: 23704086
[TBL] [Abstract][Full Text] [Related]
4. Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways.
Kumar S; Donti TR; Agnihotri N; Mehta K
Int J Cancer; 2014 Jun; 134(12):2798-807. PubMed ID: 24477458
[TBL] [Abstract][Full Text] [Related]
5. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
6. Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking.
Kim DS; Choi YB; Han BG; Park SY; Jeon Y; Kim DH; Ahn ER; Shin JE; Lee BI; Lee H; Hong KM; Kim SY
Oncogene; 2011 Dec; 30(48):4780-90. PubMed ID: 21625219
[TBL] [Abstract][Full Text] [Related]
7. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Transglutaminase 2 but Not of MDM2 Has a Significant Therapeutic Effect on Renal Cell Carcinoma.
Kang JH; Lee SH; Lee JS; Oh SJ; Ha JS; Choi HJ; Kim SY
Cells; 2020 Jun; 9(6):. PubMed ID: 32560270
[TBL] [Abstract][Full Text] [Related]
9. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
10. Tumor cell invasion of von Hippel Lindau renal cell carcinoma cells is mediated by membrane type-1 matrix metalloproteinase.
Petrella BL; Brinckerhoff CE
Mol Cancer; 2006 Dec; 5():66. PubMed ID: 17140440
[TBL] [Abstract][Full Text] [Related]
11. Changes in gene expression with increased transglutaminase 2 in a SH-SY5Y cell line.
Lee JS; Kim IH; Kim SY
Front Biosci; 2006 Sep; 11():2774-81. PubMed ID: 16720350
[TBL] [Abstract][Full Text] [Related]
12. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
Kim DS; Park SS; Nam BH; Kim IH; Kim SY
Cancer Res; 2006 Nov; 66(22):10936-43. PubMed ID: 17108131
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
14. TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor.
Shang D; Liu Y; Yang P; Chen Y; Tian Y
Urology; 2012 Apr; 79(4):966.e1-7. PubMed ID: 22341602
[TBL] [Abstract][Full Text] [Related]
15. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
[TBL] [Abstract][Full Text] [Related]
16. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Los M; Zeamari S; Foekens JA; Gebbink MF; Voest EE
Cancer Res; 1999 Sep; 59(17):4440-5. PubMed ID: 10485495
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma.
Craven RA; Hanrahan S; Totty N; Harnden P; Stanley AJ; Maher ER; Harris AL; Trimble WS; Selby PJ; Banks RE
Proteomics; 2006 Jul; 6(13):3880-93. PubMed ID: 16739133
[TBL] [Abstract][Full Text] [Related]
20. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
